Brand Name | Status | Last Update |
---|---|---|
fabrazyme | Biologic Licensing Application | 2024-07-15 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
fabry disease | Orphanet_324 | D000795 | E75.21 |
Expiration | Code | ||
---|---|---|---|
agalsidase beta, Fabrazyme, Genzyme Corporation | |||
2028-03-11 | Orphan excl. |
Code | Description |
---|---|
J0180 | Injection, agalsidase beta, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Fabry disease | D000795 | Orphanet_324 | E75.21 | — | 3 | 3 | 9 | 5 | 20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
Drug common name | Agalsidase beta |
INN | agalsidase beta |
Description | Fabrazyme (agalsidase beta) is an enzyme pharmaceutical. Agalsidase beta was first approved as Fabrazyme on 2001-08-03. It is used to treat fabry disease in the USA. It has been approved in Europe to treat fabry disease. |
Classification | Enzyme |
Drug class | enzymes |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108888 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | RZD65TSM9U (ChemIDplus, GSRS) |